NANO H5 & NANO H110 to provide result within 130 seconds
1st, June 2021: Trivitron Healthcare, a leading medical devices company has announced the launch of 2 new innovation driven products for HbA1c and Hb variant* detection. The new product includes NANO H5 & NANO H110 which are high performance liquid chromatography analyzers for HbA1c detection in less than 3 minutes.
These HPLC based HbA1c analyzers will be used for monitoring diabetes, thalassemia & hemoglobin variants.
NANO H5, is a compact, automated HPLC analyzer that uses ion exchange liquid chromatography for quantitative determination of the glycated haemoglobin (HbA1c) in human whole blood with processing time of 130 seconds that will expedite the laboratory TAT. The fully automated analyser which promises to process 5 samples at a time will take Trivitron Healthcare reach the pinnacle of precision within a designated time frame in the global diagnostic market.
NANO H110, is a compact, automated HPLC analyzer has a dual test mode for HbA1c test and Hb Variant* detection. It has some advance facilities such as Barcode scanner and cap piercing with a high sample loading capacity of 110 samples at a time which make it suitable for laboratories with medium to large workloads.
Rajesh Patel, Chief Executive Officer (IVD Business), Trivitron Healthcare on this occasion said that, “keeping in mind the increasing concern for management of diabetes and the growing demand for accurate measurement of HbA1c level, today we are delighted to announce the launch of HPLC based HbA1c analyzers - NANO H5 & NANO H110, that are compact and designed for precision.”
Trivitron Healthcare is committed to many such technological advancements in the global diagnostic field.
Since 1997, the journey of Trivitron Healthcare as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. With 13 certified manufacturing facilities in India, Finland, Turkey; Trivitron spearheads innovation in the fields of COVID-19 Products, In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Newborn Screening, Critical Care and Operating Room Solutions, thus, engraving its name as a holistic healthcare provider.
Website: www.trivitron.com
*This story is published by VOH team*
Mankind Pharma invests in Actimed Therapeutics, a UK based clinical stage specia
Tata Capital Healthcare Fund infuses $ 10 mn in Mumbai Oncocare Centre
MediBuddy reports 2X growth in revenues, becomes fastest growing digital healthc
Apollo Hospitals, Ahmedabad, awarded Most Preferred Workplace 2022-23
HiMedia’s COVID-19 Detection Kit detects the BF.7 variant
AHPI Gujarat Health Talk Series
A Stalwart Climbs Another Peak
Dr. Sajan appointed Group COO of Paras Healthcare
From Learning to healing : Hematological session
Cadila Pharmaceuticals signs Investment Intention Form (IIF) with Odisha Governm
Mankind Pharma acquires majority stake in Upakarma Ayurveda
Ahmedabad doctors save Mumbai civic official’s life
BEAT-O RAISES $33 MILLION
HCG Cancer Hospital Bengaluru sets a new benchmark for Personalized cancer care
WOMEN’S WELLBEING FINDS NEW CUSTODIAN
View All